A new drug that blocks a protein channel called TRPM4 significantly stabilizes dangerous plaque buildup in arteries without shrinking it, according to a 2026 study in mice with atherosclerosis. Gram Research analysis shows the drug prevented plaque rupture—the primary cause of heart attacks—by reducing excessive cell death in blood vessel walls. While human trials are needed before this treatment becomes available, the finding identifies TRPM4 as a promising new target for preventing heart disease complications.
Researchers discovered that blocking a protein channel called TRPM4 may help stabilize dangerous plaque buildup in arteries, potentially preventing heart attacks. In a study using mice fed a high-fat diet, scientists found that a drug called 9-phenanthrol reduced the risk of plaque rupture by preventing excessive cell death and cleanup processes in blood vessel walls. While the drug didn’t shrink existing plaques, it made them less likely to break apart and cause clots. According to Gram Research analysis, this finding opens a new avenue for treating heart disease by targeting a previously unexplored mechanism of arterial damage.
Key Statistics
A 2026 research study found that blocking the TRPM4 protein channel significantly stabilized atherosclerotic plaques in mice fed a high-fat diet, reducing the risk of dangerous plaque rupture without shrinking existing plaques.
According to research reviewed by Gram, the TRPM4-blocking drug 9-phenanthrol protected human blood vessel cells from oxidized LDL damage by preventing excessive autophagy and reducing the release of adhesion molecules that promote inflammation.
A 2026 study demonstrated that TRPM4 expression levels were significantly elevated in the arteries of atherosclerotic mice, particularly in the inner blood vessel lining, suggesting this protein plays a key role in heart disease progression.
The Quick Take
- What they studied: Whether blocking a protein channel called TRPM4 could help prevent or improve atherosclerosis (plaque buildup in arteries that leads to heart disease)
- Who participated: Laboratory mice genetically prone to heart disease were fed a high-fat diet for 16 weeks to develop plaque buildup, then treated with either a TRPM4-blocking drug or a placebo
- Key finding: The TRPM4-blocking drug didn’t shrink existing plaques but significantly stabilized them, making them less likely to rupture and cause dangerous blood clots
- What it means for you: This research suggests a new potential drug target for heart disease prevention, though human trials are needed before any treatment becomes available. People with heart disease risk factors should continue following proven prevention strategies like exercise, healthy eating, and medication as prescribed by their doctors
The Research Details
Scientists used mice that were genetically engineered to develop heart disease naturally. These mice were fed a high-fat diet for 16 weeks to speed up plaque formation in their arteries. Half the mice received a drug called 9-phenanthrol that blocks the TRPM4 protein channel, while the other half received no treatment. Researchers then examined the plaques in the mice’s arteries to see if the drug made a difference.
The team also conducted laboratory experiments using human blood vessel cells exposed to oxidized LDL (the harmful form of cholesterol). They tested whether blocking TRPM4 protected these cells from damage caused by the bad cholesterol. This two-pronged approach—studying both whole animals and individual cells—helped researchers understand how the drug works at different levels.
The researchers measured several outcomes including plaque size, plaque stability, cell death rates, and the activity of specific proteins involved in cell damage and cleanup processes. This comprehensive approach allowed them to identify exactly which cellular mechanisms the drug was affecting.
This research approach is important because it bridges the gap between basic cell biology and whole-body disease. By studying both isolated cells and living animals, researchers could confirm that blocking TRPM4 actually works in a realistic disease setting, not just in a test tube. The focus on plaque stability rather than just plaque size is particularly valuable because rupturing plaques cause heart attacks, not the plaques themselves.
This is original research published in a peer-reviewed scientific journal, which means other experts reviewed it before publication. However, the study was conducted only in mice, not humans, so results may not directly apply to people. The specific sample sizes for animal groups weren’t clearly stated in the abstract, which is a minor limitation. The laboratory experiments using human cells add credibility by showing the mechanism works in human tissue, even though it’s outside the body.
What the Results Show
The researchers found that TRPM4 protein levels were significantly higher in the arteries of mice with atherosclerosis compared to healthy mice, especially in the inner lining of blood vessels. When they gave mice the TRPM4-blocking drug 9-phenanthrol, it didn’t reduce the total amount of plaque that had already formed. However, the drug did make the existing plaques more stable and less likely to rupture—a critical finding because plaque rupture is what typically triggers heart attacks and strokes.
In laboratory experiments with human blood vessel cells exposed to oxidized LDL (bad cholesterol), blocking TRPM4 protected the cells from damage. The drug prevented excessive cell death and reduced the release of sticky molecules that help blood clots form. It also slowed down a cellular cleanup process called autophagy that, when overactive, can paradoxically harm cells rather than help them.
The researchers identified the specific mechanism: oxidized LDL activates TRPM4, which then triggers a chain reaction involving a protein called AMPK and another protein called Beclin1. This chain reaction causes excessive autophagy and cell death. By blocking TRPM4, the drug interrupts this harmful cascade, protecting blood vessel cells from damage.
The study found that blocking TRPM4 reduced the release of adhesion molecules (ICAM-1, VCAM-1, and E-selectin) from damaged blood vessel cells. These molecules are like ‘sticky tags’ that help immune cells and cholesterol attach to vessel walls, worsening inflammation. The drug also improved cell migration ability in damaged vessels, suggesting it helps maintain healthy blood vessel function. Additionally, when researchers used a different method to increase AMPK activity (using a drug called AICAR), it reversed the protective effects of TRPM4 blocking, confirming that AMPK is a key part of the mechanism.
Previous research showed that TRPM4 channels are involved in endothelial dysfunction (damage to the inner lining of blood vessels), but no one had specifically studied whether TRPM4 contributes to atherosclerosis development. This study fills that gap by demonstrating that TRPM4 is indeed involved in heart disease progression. The finding that blocking TRPM4 stabilizes plaques without shrinking them is novel and suggests a different therapeutic approach than most current heart disease drugs, which focus on reducing cholesterol and plaque size.
The study was conducted only in mice with genetically modified susceptibility to heart disease, so results may not directly translate to humans with naturally occurring heart disease. The drug was tested only in laboratory conditions and animal models, not in human patients. The study doesn’t tell us whether long-term use of TRPM4-blocking drugs would be safe or effective in people. Additionally, the research focused on one specific drug (9-phenanthrol) and one disease mechanism, so other TRPM4 blockers or combination therapies weren’t tested. The study also didn’t examine whether the drug could help people who already have advanced heart disease or whether it could prevent heart disease in healthy people.
The Bottom Line
Based on this research, TRPM4 blockers represent a promising new direction for heart disease treatment, but they are not yet available for human use. Current evidence is strong that this mechanism is involved in atherosclerosis in mice, but confidence is moderate for human application since human trials haven’t been conducted. People concerned about heart disease should continue following established prevention strategies: maintain a healthy diet low in saturated fat, exercise regularly, maintain a healthy weight, don’t smoke, and take prescribed medications like statins if recommended by their doctor. This research suggests future treatment options but doesn’t change current medical advice.
This research is most relevant to people at high risk for heart disease, including those with family history of early heart attacks, high cholesterol, high blood pressure, or diabetes. Cardiologists and pharmaceutical researchers should pay close attention as they develop new treatments. People already taking heart disease medications should not change their treatment based on this research—it’s too early. Healthy people without risk factors don’t need to take any action based on this study, though maintaining a healthy lifestyle remains important.
If TRPM4 blockers move forward to human trials, it typically takes 5-10 years for a new drug to progress from animal studies to FDA approval. Even if successful in trials, the drug would likely be used as part of a combination therapy with existing heart disease medications rather than as a standalone treatment. Benefits in plaque stabilization might take weeks to months to develop, similar to other cardiovascular medications.
Frequently Asked Questions
What is TRPM4 and why does it matter for heart disease?
TRPM4 is a protein channel in blood vessel cells that becomes overactive when exposed to bad cholesterol. A 2026 study found that blocking TRPM4 stabilizes dangerous arterial plaques, reducing heart attack risk. This makes it a promising new drug target for preventing cardiovascular disease.
Can I take a TRPM4-blocking drug to prevent heart disease right now?
No, TRPM4-blocking drugs are not yet available for human use. This research was conducted in mice and laboratory cells. Researchers must conduct human clinical trials before any drug can be approved. Current heart disease prevention relies on proven strategies like exercise, healthy diet, and prescribed medications.
How does blocking TRPM4 prevent heart attacks if it doesn’t shrink plaque?
Heart attacks typically occur when plaques rupture and form blood clots, not from plaque size alone. A 2026 study showed that blocking TRPM4 stabilizes plaques and prevents excessive cell death in blood vessel walls, making rupture less likely and reducing heart attack risk.
When will TRPM4-blocking drugs be available for patients?
If development proceeds successfully, TRPM4-blocking drugs could take 5-10 years to reach patients after human trials begin. The drug would likely be combined with existing heart disease medications rather than used alone. Current prevention strategies remain the most reliable approach.
Should I change my heart disease treatment based on this research?
No, continue taking prescribed heart disease medications as directed by your doctor. This research is preliminary and hasn’t been tested in humans yet. Proven strategies like statins, blood pressure medications, exercise, and diet modifications remain the standard of care for heart disease prevention.
Want to Apply This Research?
- Users could track cardiovascular risk factors that TRPM4 blockers might eventually help manage: weekly measurements of diet quality (servings of vegetables, saturated fat intake), exercise frequency and duration, and any changes in cholesterol levels from blood tests. This creates a baseline for comparing against future treatments.
- Users can start implementing the lifestyle changes that research shows reduce atherosclerosis risk: aim for 150 minutes of moderate exercise weekly, reduce saturated fat intake, increase fiber consumption, and maintain a healthy weight. The app could send reminders about these evidence-based prevention strategies while monitoring for future TRPM4-blocking drug availability.
- Set up quarterly reviews of cardiovascular health markers (cholesterol levels, blood pressure, weight, exercise consistency) to track progress. When TRPM4-blocking drugs become available, users can work with their doctors to monitor plaque stability through imaging tests and compare their cardiovascular outcomes to baseline measurements.
This research describes findings from animal studies and laboratory experiments. TRPM4-blocking drugs are not currently approved for human use and have not been tested in clinical trials. This article is for educational purposes only and should not be interpreted as medical advice. People with heart disease or cardiovascular risk factors should consult their healthcare provider about appropriate prevention and treatment strategies. Do not change any prescribed medications or treatments based on this research. Always follow your doctor’s recommendations for managing heart disease risk.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.